Coldstream Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.11M | Buy |
5,115
+453
| +10% | +$86.7K | 0.01% | 459 |
|
|
2026
Q1 | $855K | Sell |
4,662
-120
| -3% | -$22.1K | 0.01% | 511 |
|
|
2025
Q4 | $842K | Buy |
4,782
+302
| +7% | +$49.3K | 0.01% | 508 |
|
|
2025
Q3 | $628K | Buy |
4,480
+1,234
| +38% | +$167K | 0.01% | 635 |
|
|
2025
Q2 | $408K | Sell |
3,246
-116
| -3% | -$14.5K | 0.01% | 744 |
|
|
2025
Q1 | $460K | Buy |
3,362
+567
| +20% | +$81.1K | 0.01% | 649 |
|
|
2024
Q4 | $427K | Buy |
2,795
+398
| +17% | +$67.1K | 0.01% | 670 |
|
|
2024
Q3 | $459K | Sell |
2,397
-300
| -11% | -$62.8K | 0.01% | 641 |
|
|
2024
Q2 | $625K | Buy |
2,697
+435
| +19% | +$94.5K | 0.02% | 465 |
|
|
2024
Q1 | $488K | Sell |
2,262
-20
| -0.9% | -$4.68K | 0.01% | 560 |
|
|
2023
Q4 | $591K | Buy |
2,282
+333
| +17% | +$81.8K | 0.02% | 439 |
|
|
2023
Q3 | $501K | Sell |
1,949
-241
| -11% | -$64.5K | 0.02% | 418 |
|
|
2023
Q2 | $624K | Buy |
2,190
+40
| +2% | +$11.9K | 0.02% | 373 |
|
|
2023
Q1 | $598K | Sell |
2,150
-20
| -0.9% | -$5.53K | 0.02% | 379 |
|
|
2022
Q4 | $601K | Buy |
+2,170
| New | +$613K | 0.02% | 370 |
|
|
2022
Q2 | $408K | Buy |
2,002
+799
| +66% | +$163K | 0.02% | 460 |
|
|
2022
Q1 | $253K | Sell |
1,203
-269
| -18% | -$58.5K | 0.01% | 644 |
|
|
2021
Q4 | $353K | Buy |
1,472
+378
| +35% | +$97.2K | 0.01% | 550 |
|
|
2021
Q3 | $310K | Sell |
1,094
-76
| -6% | -$24.9K | 0.02% | 305 |
|
|
2021
Q2 | $405K | Buy |
1,170
+285
| +32% | +$86.3K | 0.02% | 313 |
|
|
2021
Q1 | $248K | Sell |
885
-199
| -18% | -$53.7K | 0.01% | 366 |
|
|
2020
Q4 | $265K | Buy |
+1,084
| New | +$280K | 0.02% | 319 |
|
|
2020
Q3 | – | Sell |
-772
| Closed | -$207K | – | 309 |
|
|
2020
Q2 | $207K | Sell |
772
-44
| -5% | -$13.2K | 0.02% | 291 |
|
|
2020
Q1 | $258K | Sell |
816
-177
| -18% | -$53.7K | 0.03% | 222 |
|
|
2019
Q4 | $294K | Buy |
993
+99
| +11% | +$27.5K | 0.02% | 258 |
|
|
2019
Q3 | $208K | Buy |
+894
| New | +$208K | 0.02% | 309 |
|
|
2018
Q4 | – | Sell |
-742
| Closed | -$262K | – | 320 |
|
|
2018
Q3 | $262K | Buy |
+742
| New | +$255K | 0.02% | 285 |
|
|
2018
Q1 | – | Sell |
-987
| Closed | -$314K | – | 290 |
|
|
2017
Q4 | $314K | Buy |
987
+225
| +30% | +$72.2K | 0.03% | 236 |
|
|
2017
Q3 | $239K | Buy |
+762
| New | +$226K | 0.03% | 262 |
|
Other funds holding BIIB
Coldstream Capital Management's BIIB Position: Q2 2026 in Review
Coldstream Capital Management increased its Biogen (BIIB) stake by 9.7% in Q2 2026, buying an estimated $86.7K and bringing the position to 5,115 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #459.
Coldstream Capital Management first reported a position in BIIB in Q3 2017 and has held it in 29 quarters since. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Coldstream Capital Management held 5,115 shares of Biogen worth $1.11M as of Q2 2026.
- Coldstream Capital Management bought 453 Biogen shares in Q2 2026, an estimated $86.7K.
- Biogen made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #459 holding.
- Coldstream Capital Management first reported a position in Biogen in Q3 2017 and has held it in 29 quarters since.
- 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.